KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Gross Margin for 6 consecutive years, with 88.87% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin fell 223.0% year-over-year to 88.87%, compared with a TTM value of 88.93% through Sep 2025, up 168.0%, and an annual FY2024 reading of 87.99%, down 395.0% over the prior year.
  • Gross Margin was 88.87% for Q3 2025 at Aurinia Pharmaceuticals, down from 89.84% in the prior quarter.
  • Across five years, Gross Margin topped out at 98.82% in Q1 2022 and bottomed at 84.42% in Q2 2024.
  • Average Gross Margin over 5 years is 92.3%, with a median of 92.71% recorded in 2024.
  • The sharpest move saw Gross Margin crashed -1419bps in 2024, then surged 541bps in 2025.
  • Year by year, Gross Margin stood at 97.94% in 2021, then fell by -3bps to 95.21% in 2022, then dropped by -8bps to 88.04% in 2023, then increased by 3bps to 90.73% in 2024, then decreased by -2bps to 88.87% in 2025.
  • Business Quant data shows Gross Margin for AUPH at 88.87% in Q3 2025, 89.84% in Q2 2025, and 86.27% in Q1 2025.